Obtain Parkinson’s disease (PD) patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI).

Previous data from the ongoing InfusON study demonstrated that CSAI consistently reduced OFF-time, improved Good ON-time (without troublesome dyskinesia), and was generally safe over a 52-Week Maintenance Period.

The InfusON study (NCT02339064), enrolled levodopa-treated PD patients in the U.S. with unsatisfactory motor fluctuation control despite oral medication optimization. CSAI was initiated in an outpatient clinic with a 1-2 mg bolus followed by 1 mg/h infusion titrated to optimal efficacy and tolerability (not to exceed 8 mg/h or 150 mg/day), followed by a 52-week Maintenance Period. A patient experience survey was conducted with 19 consenting patients (from 9 sites) who completed the Maintenance and entered an Extension Period allowing continued therapy until commercial availability.

Surveys indicated that 63% of patients could independently initiate CSAI therapy while the rest had help. Respondents quickly developed confidence with setting up the infusion and wearing the device, with 79% being comfortable setting up and 68% adapting to wearing the device within about 2 weeks. Once adapted to the device, 16% of patients reported discomfort, though this did not lead to discontinuation. While 74% of patients initially required >10 minutes to set up, 89% were able to set up in about 5 to 10 minutes once they adjusted to the process. Though patients reported alternating infusion sites on the body, the most frequently used locations were the abdomen and upper arms/shoulders. Overall, 95% of patients would recommend CSAI to other individuals needing treatment for PD motor fluctuations.

Patient experience is a key driver of how long patients remain on therapy. This survey showed that patients quickly adapt and easily incorporate CSAI into their routine. Most patients would recommend CSAI to other people with PD.